INO-9012 is named as a drug or biological intervention in 2 clinical trials in our USA trial register, 1 of which is recruiting. Lead sponsors include Inovio Pharmaceuticals (1) and Geneos Therapeutics (1). Registered phases: Phase 1/2 and Phase 2. Conditions studied include Glioblastoma; HCC.
| NCT ID | Study | Phase | Status |
|---|---|---|---|
| NCT07722741 | Personalized Neoantigen Vaccine Plus IL-12 (INO-9012) Versus Active Surveillance in Subjects With High-Risk HCC (ClinicalTrials.gov ↗) HCC |
Phase 2 | Recruiting |
| NCT03491683 | INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With Cemiplimab (REGN2810) in Newly-Diagnosed Glioblastoma (GBM) Glioblastoma |
Phase 1/2 | Active, closed |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| Glioblastoma | 1 |
| HCC | 1 |
| Lead sponsor | Trials |
|---|---|
| Inovio Pharmaceuticals | 1 |
| Geneos Therapeutics | 1 |
| Register | INO-9012 trials |
|---|---|
| Clinical trials in USA | 2 |
A trial with sites in more than one country appears in each of those registers.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how INO-9012 works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists INO-9012 (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 24 Sep 2026.